The Garrahan Hospital enthusiastically announced a new research project that promises to revolutionize the treatment of retinoblastoma and benefit children from different parts of the world. Researcher Franco Benvenuto, leader of this project, emphasized the importance of research for patients with this disease, especially those in low-resource countries.
The project involves specialists from various departments of the Garrahan Hospital, as well as collaborators from the University of Buenos Aires and the Jules Gonin Hospital in Switzerland. The Association for Research in Vision and Ophthalmology (ARVO) provided a grant to Benvenuto to carry out this innovative research aimed at developing more accessible and effective treatments for retinoblastoma.
Retinoblastoma is the most common eye tumor in children, with high cure rates if diagnosed and treated on time. The funding received will contribute to deepening research at Garrahan Hospital, which is globally recognized for its advances in Pediatrics and Youth Health.
The project led by Paula Schaiquevich aims to evaluate the efficacy and safety of new chemotherapeutic drugs for retinoblastoma. The use of gemcitabine, a chemotherapeutic agent that has shown effectiveness against this type of tumor in previous studies, will be explored.
The initiative represents a significant step in the search for more effective and less toxic treatments for retinoblastoma. Experts from different clinical and academic centers are collaborating on this translational research project that promises to improve the quality of life of children with eye cancer.
Despite budget cuts, the Garrahan Hospital continues its research and patient care efforts, standing out for its commitment to the health of young people.
